Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype
Annals of the Rheumatic Diseases · 2025-11 · 84 (11) · 1836-1851
DOI: 10.1016/j.ard.2025.07.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025-11. Verfasst von Jessica Neely und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Jessica.Neel…. Hauptthemen laut MEDLINE: Dermatomyositis, Autoantibodies, Proteome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIAMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status. METHODS: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls. Twenty-four patients with JDM who had 6-month follow-up samples were assessed. We identified differentially expressed proteins (DEPs) between groups by fitting linear mixed effects models and associated DEPs with validated disease activity measures. We assessed for cell/tissue specificity using the Human Protein Atlas and JDM muscle single nuclei and skin single-cell transcriptomic datasets. Differences within MSA subgroups were also analysed. RESULTS: We uncovered persistent dysregulation of innate immune activation, cell death, and redox signalling at 6 months despite multidrug immunosuppression. By leveraging tissue and cell-specific proteomes, we identified overrepresentation of circulating endothelial proteins associated with disease activity and verified endothelial cell marker expression in JDM muscle and skin. We discovered pathways associated with MSA subtypes that reflect JDM phenotypes. NXP2+ JDM-associated proteins reflected angiogenesis and extracellular matrix remodelling and were expressed in endothelial cells and fibroblasts. MDA5+ JDM was associated with circulating type III interferon and surfactant proteins. CONCLUSIONS: These proteomic findings will inform future biomarker and treatment development considering the unique tissue- and autoantibody-associated inflammation in JDM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Jessica.Neely@ucsf.edu.
- Department of Pediatrics, Division of Rheumatology, The Medical College of Wisconsin, Milwaukee, WI, USA.
- Department of Pediatrics, Division of Rheumatology, Duke University, Durham, NC, USA.
- Department of Pediatrics, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA.
- Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA.
- Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Förderung
- Intramural NIH HHS
- NIAMS NIH HHS
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- George M. O'Brien Michigan Kidney Translational Core Center
- Cure JM Foundation
- Childhood Arthritis and Rheumatology Research Alliance
Zitieren
APA
Neely, J., Sabbagh, S. E., Dvergsten, J., Madubata, C., Berthier, C. C., Zheng, Z., Goudsmit, C., Matossian, S., Ferris, S. P., Fragiadakis, G. K., Sirota, M., Kahlenberg, J. M., Kim, H., Turnier, J. L., & CARRA Registry Investigators and CARRA Translational Medicine for Juvenile Myositis Working Group (2025). Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype. Annals of the Rheumatic Diseases, 84(11), 1836-1851. https://doi.org/10.1016/j.ard.2025.07.020
Vancouver
Neely J, Sabbagh SE, Dvergsten J, Madubata C, Berthier CC, Zheng Z, et al. Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype. Annals of the Rheumatic Diseases. 2025;84(11):1836-1851. doi:10.1016/j.ard.2025.07.020
BibTeX
@article{Neely2025,
author = {Neely, Jessica and Sabbagh, Sara E and Dvergsten, Jeffrey and Madubata, Chioma and Berthier, Celine C and Zheng, Zilan and Goudsmit, Christine and Matossian, Sophia and Ferris, Sean P and Fragiadakis, Gabriela K and Sirota, Marina and Kahlenberg, J Michelle and Kim, Hanna and Turnier, Jessica L and CARRA Registry Investigators and CARRA Translational Medicine for Juvenile Myositis Working Group, CARRA Registry Investigators and CARRA Translational Medicine for Juvenile Myositis Working Group},
title = {Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
number = {11},
pages = {1836--1851},
doi = {10.1016/j.ard.2025.07.020}
}
EUVIMED